Haleon plc (LON:HLN) Given Average Recommendation of “Moderate Buy” by Brokerages

Haleon plc (LON:HLN) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 407.83.

Several analysts recently issued reports on HLN shares. JPMorgan Chase & Co. upped their price objective on shares of Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a report on Wednesday, November 26th. Jefferies Financial Group reissued a “buy” rating and set a GBX 450 target price on shares of Haleon in a research report on Wednesday, January 21st. Berenberg Bank raised their price target on Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 price objective on shares of Haleon in a research note on Friday, October 31st. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a research note on Thursday, January 22nd.

Haleon Stock Up 0.6%

Shares of Haleon stock opened at GBX 409.20 on Monday. Haleon has a 12-month low of GBX 325.10 and a 12-month high of GBX 419.50. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The stock has a 50 day moving average price of GBX 375.13 and a two-hundred day moving average price of GBX 362.08. The stock has a market capitalization of £36.44 billion, a P/E ratio of 24.50, a PEG ratio of 1.49 and a beta of 0.19.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.